Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (NASDAQ: CORT) generates frequent news as a commercial-stage pharmaceutical company focused on cortisol modulation in endocrinology, oncology, metabolic disease and neurology. Company updates often highlight progress with Korlym, which Corcept describes as the first FDA-approved medication for patients with endogenous hypercortisolism, and with a pipeline of selective glucocorticoid receptor antagonists and other cortisol modulators.
News about Corcept commonly covers clinical trial milestones in hypercortisolism, solid tumors, ALS and liver disease. Examples include data from the CATALYST program in patients with difficult-to-control type 2 diabetes and hypercortisolism, the pivotal ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, the BELLA Phase 2 trial in gynecologic cancers, the MONARCH Phase 2b trial in MASH, and the DAZALS trial of dazucorilant in ALS. Company communications also describe upcoming or ongoing studies of nenocorilant in combination with immunotherapy in solid tumors.
Investors following CORT news will see regular regulatory and corporate announcements, such as New Drug Application (NDA) submissions and FDA acceptance for review of relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application (MAA) to the European Medicines Agency, and an FDA Complete Response Letter requesting additional evidence of effectiveness for relacorilant in hypertension secondary to hypercortisolism. Quarterly earnings releases and corporate updates, reported via press releases and Form 8-K filings, provide information on product revenue from Korlym, operating expenses and the company’s cash and investment position.
This CORT news page on Stock Titan aggregates these public disclosures so readers can monitor Corcept’s clinical data presentations, regulatory milestones, financial results and other material events in one place. Users interested in endocrine disorders, ovarian cancer, MASH, ALS or cortisol biology can review the evolving news flow to understand how Corcept’s programs are progressing over time.
Corcept Therapeutics (NASDAQ: CORT) will report first quarter 2026 financial results and provide a corporate update on April 30, 2026. A conference call is scheduled for 5:00 p.m. ET / 2:00 p.m. PT. Participants must register in advance to receive a dial-in and unique access PIN. A listen-only webcast will be available and a replay will be posted on the Investors / Events tab of Corcept.com.
Corcept (NASDAQ: CORT) will present new subgroup overall survival data from the pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at ASCO 2026 on May 29, 2026.
Lifyorli was approved by the FDA in March 2026 and is listed as a preferred regimen in NCCN Guidelines for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Corcept (NASDAQ: CORT) presented final Phase 3 ROSELLA results showing Lifyorli (relacorilant) plus nab-paclitaxel reduced risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival by 4.1 months (16.0 vs 11.9 months) in platinum-resistant ovarian cancer.
The regimen also cut progression risk by 30% (HR 0.70; p=0.0076), was well tolerated versus chemotherapy alone, received FDA approval in March 2026, and was added to NCCN Guidelines as a preferred regimen.
Corcept Therapeutics (NASDAQ: CORT) presented late-breaking MOMENTUM trial data at ACC 2026 showing 27.3% prevalence of endogenous hypercortisolism among 1,086 patients with resistant hypertension (297 patients).
The results align with Corcept’s CATALYST trial and show higher prevalence (32.6%–36.6%) in high‑risk subgroups with elevated HbA1c and multi‑drug blood pressure regimens.
Corcept Therapeutics (NASDAQ: CORT) announced FDA approval on March 25, 2026 for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens, including at least one with bevacizumab.
Approval followed the 381‑patient ROSELLA trial: OS benefit of 4.1 months (16.0 vs 11.9 months; HR 0.65; p=0.0004) and PFS improvement (HR 0.70; p=0.008). Lifyorli is the first FDA‑approved selective glucocorticoid receptor antagonist; safety notes include neutropenia, infections, adrenal insufficiency and embryo‑fetal toxicity.
Corcept Therapeutics (NASDAQ: CORT) reported 2025 revenue of $761.4M and net income of $99.7M. Fourth-quarter revenue was $202.1M with Q4 net income of $24.3M (diluted EPS $0.20). Cash and investments totaled $532.4M at year-end. Management provided 2026 revenue guidance of $900M–$1,000M and highlighted key clinical readouts, a July 11, 2026 PDUFA date for relacorilant in platinum-resistant ovarian cancer, and plans for a Phase 3 ALS trial.
Corcept (NASDAQ: CORT) said the U.S. Court of Appeals for the Federal Circuit found that Teva Pharmaceuticals’ marketing of a generic Korlym does not infringe two Corcept patents covering methods for safely co-administering Korlym with CYP3A4 inhibitors.
The ruling affirms a December 2023 District Court verdict. Corcept said it is disappointed and is considering whether to seek further judicial review.
Corcept Therapeutics (NASDAQ: CORT) will report fourth quarter and full‑year 2025 financial results and provide a corporate update on February 24, 2026. A conference call and listen‑only webcast will be held at 5:00 p.m. ET (2:00 p.m. PT), with registration required for dial‑in access and PINs.
A replay will be posted on the Investors / Events tab of Corcept.com after the call.
Corcept (NASDAQ: CORT) reported that its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met both dual primary endpoints. The combination reduced the risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival to 16.0 months vs 11.9 months (difference 4.1 months). ROSELLA also showed a 30% reduction in progression risk (HR 0.70; p=0.008). The regimen was well tolerated with similar adverse event profiles versus nab-paclitaxel alone. The NDA is under FDA review with a PDUFA date of July 11, 2026, and an MAA is under EMA review. ROSELLA enrolled 381 patients randomized 1:1 across multiple regions.
Corcept (NASDAQ: CORT) announced that the FDA issued a Complete Response Letter for the NDA for relacorilant as a treatment for hypertension secondary to hypercortisolism. The FDA acknowledged the pivotal GRACE trial met its primary endpoint and found the GRADIENT trial provided confirmatory evidence, but concluded additional evidence of effectiveness is needed before a favorable benefit‑risk assessment can be made.
Corcept said it is surprised and disappointed, remains committed to patients, and will meet with the FDA as soon as possible to discuss next steps.